Avanzanite Bioscience raises €32M to accelerate rare disease treatments across Europe
Helping innovators scale more efficiently while improving access for patients
Amsterdam-based Avanzanite Bioscience has raised €32 million in Series A funding from MVM Partners, marking its first institutional investment and positioning the company for accelerated commercial growth across Europe’s rare disease landscape.
Founded in 2022, Avanzanite has rapidly become a preferred partner for biotech and pharmaceutical innovators looking to launch orphan medicines across all 32 European markets. The new capital will expand its pan-European commercial infrastructure, support upcoming product launches, and fuel new alliances and acquisitions.
The raise comes after a standout quarter: Avanzanite’s revenue tripled year on year in Q3 2025 and rose more than 20 per cent compared with Q2. In just three years, it has entered three strategic alliances and commercialised three rare disease medicines across nephrology, ophthalmology, and haematology, with exclusive rights across the EEA, UK, and Switzerland.
Avanzanite’s model addresses a long-standing challenge in Europe: the fragmented path to market for rare disease medicines. By centralising commercial strategy, scientific expertise, market access, pricing, and reimbursement, the company aims to help innovators scale more efficiently while improving access for patients across the continent.
MVM’s commitment comes from its €500 million sixth fund, with additional capital reserved for future growth. The firm will also join Avanzanite’s Board of Directors.
Amsterdam’s life sciences ecosystem continues to scale
The Amsterdam Metropolitan Area has become a strategic base for companies working life sciences and health (LSH) innovation, supported by a strong regulatory environment, the EMA’s presence, and close links between academia, hospitals, and industry.
Scale-ups such as myTomorrows, VectorY, Neogene now AstraZeneca Cell Therapy, Scenic Biotech, and LUMICKS have all contributed to the region’s rise as a European LSH hub. At the same time, global players continue to choose Amsterdam as their European headquarters or clinical operations centre. The city’s focus on cross-border health innovation and advanced therapies positions it as a preferred launch environment for companies aiming to reach patients across Europe.